methyl 1-(4-fluorophenyl)-5-pyrrolidone-3-carboxylate | 133747-62-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: methyl 1-(4-fluorophenyl)-5-pyrrolidone-3-carboxylate
• 英文别名: 1-(4-fluorophenyl)-4-methoxycarbonyl-2-pyrrolidinone；methyl 1-(4-fluorophenyl)-5-oxopyrrolidine-3-carboxylate
• CAS: 133747-62-3
• 化学式: C₁₂H₁₂FNO₃
• 分子量: 237.231
• InChiKey: YTJWOGDOCWTOTL-UHFFFAOYSA-N

物化性质

• 熔点：
  101-102 °C(Solv: ethanol (64-17-5))
• 沸点：
  422.1±40.0 °C(Predicted)
• 密度：
  1.301±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 1-(4-fluorophenyl)-5-pyrrolidone-3-carboxylate 在 甲醇 、 sodium tetrahydroborate 、 potassium carbonate 、 三乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-[1-(4-fluorophenyl)-5-oxo-pyrrolidin-3-ylmethoxy]benzoic acid methyl ester
  参考文献：
  名称：

  Synthesis of 4-[1-(substituted phenyl)-2-oxo-pyrrolidin-4-yl]methyloxybenzoic acids and related compounds, and their inhibitory capacities toward fatty-acid and sterol biosyntheses

  摘要：

  The synthesis of a series of 4[1-(substituted phenyl)-2-oxo-pyrrolidin-4-yl]methyloxybenzoic acids and related compounds, and their evaluation for inhibitory capacity toward fatty-acid and sterol biosyntheses using rats' liver slices in vitro and rabbits in vivo, are described. Among the compounds synthesized, 7e, 7g, 7h, 7i, 7k, 7r, 21, 23 and 29a b showed a potent inhibitory activity toward fatty-acid and sterol biosyntheses. Their IC(50)s were 4.4-6.8 x 10(-6) M and 6.6-9.8 x 10(-6) M, respectively. These activities were always superior to those of compounds I, II, III and Clinofibrate as references. The inhibitory activity toward the sterol biosynthesis of these compounds was inferior to that of Pravastatin. The reducing effects of the representative compounds (7e and 7l) toward plasma cholesterols and triglyceride were evaluated in Japanese white rabbits (30 and 100 mg/kg, po) and compared with those of Clinofibrate:and Pravastatin; The compounds showed a similar hypocholesterolemic effect to Pravastatin and a more potent hypotriglycemic effect than Clinofibrate and Pravastatin in this animal model. Thus, a dual,action of hypolipidemic effects was noted in 7e and 7l compared with the references.

  DOI：

  10.1016/0223-5234(94)90029-9
• 作为产物：
  描述：

  衣康酸 在 草酰氯 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 methyl 1-(4-fluorophenyl)-5-pyrrolidone-3-carboxylate
  参考文献：
  名称：

  发现具有潜在诱导的系统抗性的新型植物活化剂和支架：从茉莉酸到吡咯烷酮†

  摘要：

  由于病原体，昆虫和某些特定微生物的感染，或者经过特定化学物质的处理，植物会发展出多方面的系统抗性。1其中，系统性获得性抵抗力（SAR）和诱导性系统抵抗力（ISR）2是两个最重要的类型。为了激活它们，已经基于SA途径开发了大量化学诱导剂。但是，对于新的植物激活剂，很少研究JA途径。在这项研究中，从JA及其类似物出发，基于分子三维形状和药效基团相似性比较（SHAFTS），预测了一种新的先导化合物吡咯烷酮，它将作为一种植物激活剂的新支架，并形成一系列1-苯基设计并合成了-5-吡咯烷酮-3-羧酸衍生物。对生物活性进行了评估，大多数化合物均显示出令人满意的活性。特别是化合物7-11在体外几乎没有显示 活性，但对被测疾病具有优异的疗效，并证实了虚拟筛选结果的预测，这促进了SHAFTS在农药开发中的应用。

  DOI：

  10.1039/c6md00261g

文献信息

• CALCIUM RECEPTOR MODULATING AGENTS
  申请人：Coulter Thomas S.

  公开号：US20110178133A1

  公开（公告）日：2011-07-21

  The present invention relates generally to novel calcimimetic compounds and pharmaceutical compositions comprising them. The invention also relates to methods of treating of diseases or disorders related to the function of the calcium sensing receptor using the compounds represented in Formula I.

  本发明通常涉及新型钙敏感受体激动剂化合物及包含它们的制药组合物。本发明还涉及使用公式I中所代表的化合物治疗与钙感受受体功能相关的疾病或障碍的方法。
• Calcium receptor modulating agents
  申请人：Amgen Inc.

  公开号：US08334317B2

  公开（公告）日：2012-12-18

  The present invention relates generally to novel calcimimetic compounds and pharmaceutical compositions comprising them. The invention also relates to methods of treating of diseases or disorders related to the function of the calcium sensing receptor using the compounds represented in Formula I.

  本发明涉及一种新型的钙敏感受体激动剂化合物和包含它们的药物组合物。该发明还涉及使用式I中所表示的化合物治疗与钙感受受体功能相关的疾病或疾病的方法。
• Lp(a)-LOWERING AGENTS AND APOPROTEIN (a) PRODUCTION INHIBTORS
  申请人：TAIHO PHARMACEUTICAL COMPANY, LIMITED

  公开号：EP1000620A1

  公开（公告）日：2000-05-17

  Lp(a)-lowering agents or apo(a) production inhibitors containing as the active ingredient phenylcarboxylic acid derivatives represented by general formula (1) or salts thereof, wherein R1 represents optionally substituted phenyl; A represents lower alkylene or lower alkyleneoxy; B represents methylene or carbonyl; D represents lower alkylene; E represents lower alkylene or lower alkenylene; R2 represents hydrogen or lower alkyl; and l, m and n are each 0 or 1. These drugs can significantly lower Lp(a) while scarcely showing any side effects.

  Lp(a)降低剂或apo(a)生成抑制剂，其活性成分为通式(1)代表的苯基羧酸衍生物或其盐类，其中R1代表任选取代的苯基；A代表低级亚烷基或低级亚烷氧基；B代表亚甲基或羰基；D代表低级亚烷基；E代表低级亚烷基或低级亚烯基；R2代表氢或低级亚烷基；l、m和n均为0或1。这些药物可以大大降低脂蛋白（a），同时几乎没有任何副作用。
• Nickel-catalysed reductive C–N bond cross-coupling between aryl halides and N-chloroamides
  作者：Yiting Luo、Jiacan Yao、Yunzhi He、Chang Xu、Dandan Liu

  DOI：10.1039/d4ob00970c

  日期：——

  A method for the direct synthesis of N-aryl lactams and amides with aryl halides and N-chloroamides through a Ni-catalyzed reductive C–N coupling reaction has been developed. The reaction features the advantages of mild conditions, good functional group tolerance and broad substrate scope including drug-derived substrates, and also provided direct access to the key synthetic intermediates for some

  开发了一种通过 Ni 催化还原 C-N 偶联反应直接合成N-芳基内酰胺和酰胺与芳基卤和N-氯酰胺的方法。该反应具有条件温和、官能团耐受性好、底物范围广泛（包括药物衍生底物）等优点，并且还为一些生物活性分子的关键合成中间体提供了直接途径，表明该方法的实用性。最后，进行DFT计算以进一步阐明反应机理，发现可能涉及酰胺基。
• Cyclization products of N-fluorophenyl-β-alanines and their properties
  作者：R. Vaickelioniene、V. Mickevicius

  DOI：10.1007/s10593-006-0157-4

  日期：2006.6